Voyager Therapeutics, Inc. - 10-Q Filing

Voyager Therapeutics reports third quarter 2026 financial results including updates on Tau and SOD1 gene therapy programs.

SEC EDGAR ·

Tickers: $VYGR

Read the full article at SEC EDGAR

More Regulatory news